MRC1 and neoplasm: The second assessment amongst POLE wildtype (POLEwt) tumours is the loss of expression in one or more of the 4 mismatch repair (MMR) proteins (MLH1, MSH2, MSH6 or PMS2) categorised as the MMR-deficient (MMRd) EC.